Preferred Label : PD-1 Targeted IL-15 Mutein Fusion Protein PF-07209960;
NCIt synonyms : PD-1 Targeting Interleukin-15 Mutein Fusion Protein PF-07209960; Anti-PD-1/IL-15 Mutein Fusion Protein PF-07209960;
NCIt definition : A fusion protein composed of a moiety targeting the negative immunoregulatory human
cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279) fused to a mutein
of the cytokine interleukin-15 (IL-15), with potential immune checkpoint inhibitory,
immunomodulating and antineoplastic activities. Upon administration of PD-1 targeted
IL-15 mutein fusion protein PF-07209960, the PD-1 targeting moiety specifically targets,
binds to and inhibits PD-1 and its downstream signaling pathways. This may restore
immune function through the activation of T-cells and T-cell-mediated immune responses
against tumor cells. The IL-15 mutein moiety binds to the IL-15 receptor and activates
IL-15 cytokine signaling. This stimulates the proliferation of natural killer (NK)
cells, cytotoxic T-lymphocytes (CTLs) and memory T-cells locally in the tumor microenvironment
(TME), and induces an anti-tumor immune response. This may increase tumor cell killing
and decrease tumor cell proliferation. PD-1, a transmembrane protein in the immunoglobulin
superfamily (IgSF) expressed on T-cells, functions as an immune checkpoint that negatively
regulates T-cell activation and effector function when activated by its ligands programmed
cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274) or 2 (PD-L2);
it plays an important role in tumor evasion from host immunity. IL-15 regulates CD8
T and NK cell development, activation and proliferation.;
Molecule name : PF 07209960; PF-07209960;
NCI Metathesaurus CUI : CL1642927;
Origin ID : C176870;
UMLS CUI : C5447484;
Semantic type(s)
- concept_is_in_subset
- has_target
